T-knife Therapeutics Inc. has filed a clinical trial application (CTA) to initiate a phase I trial of TK-6302, a PRAME-targeted T-cell receptor (TCR) T-cell therapy in solid tumors. Pending CTA approval, the ATLAS trial is planned to begin next year.
Captain T Cell GmbH has successfully closed an equity financing round to support its T-cell receptor (TCR) T-cell therapies for solid tumors. The company’s autologous lead program, CTC-127, is a best-in-class TCR T-cell therapy targeting MAGE-A4-positive solid tumors and is expected to enter clinical trials in early 2027.
Anocca AB has submitted its first clinical trial application (CTA) to the EMA for a phase I/II multi-asset umbrella trial, VIDAR-1. The application covers ANOC-001 as the initial product in the VIDAR-1 program targeting mutated KRAS in advanced pancreatic cancer.
On the heels of U.S. FDA approval of its first T-cell therapy, Adaptimmune Therapeutics plc reported positive results from a pivotal study for its second candidate, letetresgene autoleucel, expected to support a rolling BLA submission in 2025 that could bolster the firm’s offerings as it narrows its focus on the rare sarcoma space.
Medigene AG has obtained FDA clearance of its IND application for lead program MDG-1015 for the treatment of advanced gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma.
Medigene AG has selected its lead candidate for MDG-2021, a T-cell receptor engineered T-cell (TCR-T) therapy targeting KRAS G12D with human leukocyte antigen (HLA)-A*11 being developed in combination with the company’s PD1-41BB costimulatory switch protein (CSP) technology.
α-Fetoprotein (AFP) is a tumor-associated antigen and an ideal target for T-cell receptor T-cell (TCR-T) therapy. While the safety of AFP-targeting TCR-T products has been previously demonstrated in early clinical trials, the efficacy of these cell therapies is still modest, warranting further research.
Medigene AG has selected initial clinical indications for its lead candidate, MDG-1015, specifically gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma.
Amphiphile (AMP)-modification of peptide antigens and molecular adjuvants has been previously demonstrated to enhance lymphatic delivery and retention, resulting in potent expansion of cognate endogenous T-cell responses.
Medigene AG has announced a prioritization of its pipeline as it advances its differentiated T-cell receptor engineered T cell (TCR-T) therapies for solid tumors.
